Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models. - Wikidata - wikimedia - TriplyDB

Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models.

Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models.

http://www.wikidata.org/entity/Q36357215

about

ALK and ROS1 as targeted therapy paradigms and clinical implications to overcome crizotinib resistance Treating patients with ALK-positive non-small cell lung cancer: latest evidence and management strategy Ganetespib: research and clinical development Molecular targets in urothelial cancer: detection, treatment, and animal models of bladder cancer HSP90 inhibition enhances antimitotic drug-induced mitotic arrest and cell death in preclinical models of non-small cell lung cancer Hsp90 inhibitor SY-016 induces G2/M arrest and apoptosis in paclitaxel-resistant human ovarian cancer cells The HSP90 inhibitor ganetespib has chemosensitizer and radiosensitizer activity in colorectal cancer.A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies.The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer.The HSP90 Inhibitor Ganetespib Radiosensitizes Human Lung Adenocarcinoma Cells.Casein Kinase 2 (CK2)-mediated Phosphorylation of Hsp90β as a Novel Mechanism of Rifampin-induced MDR1 Expression Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression.Network analysis identifies an HSP90-central hub susceptible in ovarian cancer Hsp90, an unlikely ally in the war on cancer.Hsp90 Inhibitor Ganetespib Sensitizes Non-Small Cell Lung Cancer to Radiation but Has Variable Effects with Chemoradiation.Targeted inhibition of Hsp90 by ganetespib is effective across a broad spectrum of breast cancer subtypes.HSP-90 inhibitor ganetespib is synergistic with doxorubicin in small cell lung cancer.Molecular-targeted agents combination therapy for cancer: developments and potentials.New targets in non-small cell lung cancer.Tubulin inhibitors in non-small cell lung cancer: looking back and forward.Heat shock protein antagonists in early stage clinical trials for NSCLC.Radioresistant human lung adenocarcinoma cells that survived multiple fractions of ionizing radiation are sensitive to HSP90 inhibition Emerging treatment using tubulin inhibitors in advanced non-small cell lung cancer.The effect of 17-allylamino-17-demethoxygeldanamycin alone or in combination with paclitaxel on anaplastic thyroid carcinoma cells.Heat shock protein 90 promotes epithelial to mesenchymal transition, invasion, and migration in colorectal cancer.Ganetespib overcomes resistance to PARP inhibitors in breast cancer by targeting core proteins in the DNA repair machinery.HSP90 as a novel molecular target in non-small-cell lung cancer BIIB021: A novel inhibitor to heat shock protein 90-addicted oncology.Targeting Heat Shock Proteins in Cancer: A Promising Therapeutic Approach High-level expression of Hsp90β is associated with poor survival in resectable non-small-cell lung cancer patients.Implications of KRAS mutations in acquired resistance to treatment in NSCLC.Gefitinib versus erlotinib as salvage treatment for lung adenocarcinoma patients who benefited from the initial gefitinib: A retrospective study.A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1).Ganetespib targets multiple levels of the receptor tyrosine kinase signaling cascade and preferentially inhibits ErbB2-overexpressing breast cancer cells.Reactivation of the p90RSK-CDC25C Pathway Leads to Bypass of the Ganetespib-Induced G2-M Arrest and Mediates Acquired Resistance to Ganetespib in KRAS-Mutant NSCLC.

P2860

Q26775347-7DEDE549-C5AF-4D14-88D1-C571AE431E15 Q26795555-870C2141-AED0-481E-8E55-8EE0087900C6 Q26798645-6985E9C8-EA93-4929-8430-FAF0A4DDB6C2 Q28076041-610A2F7B-AE90-4568-B736-982FF1344E2E Q28542855-262C4495-950E-4948-89C6-371B09A31992 Q33598733-EA06C103-305E-4D97-9AB5-1D0AB4087417 Q33912171-DB1DFECE-394C-4789-89D4-BEAEDC57CE0A Q34636437-057D522A-E1BE-44F8-9046-7877E286475A Q35689752-DEAA72CE-A24C-4E84-96CE-E9E4407FBE5C Q35818450-7A3B2729-9784-4CFB-8BA7-D8C892A07DE1 Q35860589-764583F6-3150-4588-BF11-CAE77C2742B0 Q36642876-3C4CC475-E80F-4103-899C-CFA1264FF8B3 Q37185385-595A1DBB-EC33-41BE-A2FC-DD97725CAF30 Q37274497-14F14EFB-91D2-4AB4-A7AC-46EE4F675134 Q37470072-DA51BE4E-086D-4F70-B887-A1803499EFBD Q37554911-503B23CC-6910-4AB6-90AF-518796019ACF Q37728631-E2E86457-22A0-4814-8109-64ECEB5F33C2 Q38104670-7DB9A1BD-2207-4E29-88F5-12189B666CD2 Q38114835-C6E58FB2-2B77-4B9B-893E-7ECFDDEB9401 Q38742506-0C9953AF-6723-4180-B53C-689EE44394DA Q38748687-58E69518-534C-4FDD-AEA8-C7C4E4BB4EE8 Q38823644-54AF5CA7-1F1A-4AEF-B049-1E7D708F51CF Q38847914-D73C1B66-6B56-4D8D-A2EF-32A481D07A1B Q38968385-25FA2432-7996-401E-953B-9426DB09C5FD Q38991602-ED58D561-F731-4845-83A7-9CF672D95E30 Q39006252-3C68F16F-85C6-4257-AD0A-DD82CC1EAD78 Q39139943-6B7ED528-630D-474B-A665-4F1337D1E2CF Q39263075-3CE1BC39-EA94-4F8A-9FC1-CD7C5CCF4DC4 Q41660505-77E8D826-AD5E-47AB-AE2C-A7554500BEA3 Q48222968-8C2FF7B1-7D6A-467E-B1F0-37FA9A1BA4F9 Q49787333-1C73C53D-41D3-4A4C-82B5-E694D3F95E35 Q50050625-2C01D0AC-809D-4347-B0B8-B3B42E8D7612 Q51629344-C699DDB4-2389-4AB1-9685-34215DCE2112 Q52714930-4AA4D678-9F8D-4271-98BF-6E09DA050390 Q52767644-BC5A24F2-0902-45E2-8BF6-AF9483055633

P2860

Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models.

http://www.wikidata.org/entity/Q36357215

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Synergistic activity of the Hs ...... small cell lung cancer models.

@ast

Synergistic activity of the Hs ...... small cell lung cancer models.

@en

type

label

Synergistic activity of the Hs ...... small cell lung cancer models.

@ast

Synergistic activity of the Hs ...... small cell lung cancer models.

@en

prefLabel

Synergistic activity of the Hs ...... small cell lung cancer models.

@ast

Synergistic activity of the Hs ...... small cell lung cancer models.

@en

P1433

Q36357215-462E3772-FA19-4CDC-B57B-0A2326948621

P1476

Q36357215-E3B3AEE4-EABA-4753-A0DD-300276220DC0

P2093

Q36357215-31477021-E22E-4B23-8948-C43BB61E5EA0

Q36357215-49875DF4-FE78-48B0-84FA-76CAFE3990DC

Q36357215-76B63D95-470C-49B1-9292-8D1C5E3CEDAA

Q36357215-7C0D8DA2-2600-488C-BC36-69079E0BAA5A

Q36357215-A80D15DE-1DF9-4E49-8496-B269D4257D81

Q36357215-AB2382E5-94CF-4B20-A1EB-192F662C106E

Q36357215-B092D424-A526-42A9-974A-CFAB6276613F

Q36357215-B1B30613-6082-48EF-8394-4FD96AA516B8

Q36357215-B5BE9DCB-9BEB-4E41-8A45-B933CD75BC61

Q36357215-C33FF160-1AE4-4F0F-BC5B-6AEFF272E3CC

P2860

Q36357215-013FEEA7-E292-45B6-BFE1-0A6856A118CF

Q36357215-09E59808-4227-40B6-8094-2BF36C603529

Q36357215-1B7AD24E-7E80-482E-9709-4E94F7BD343A

Q36357215-20201EDB-3806-4E3D-9C39-D7CE21D055D9

Q36357215-338D87A3-2476-41C1-BE7F-0C879E9103A8

Q36357215-3572824E-61A9-4B2F-BCA8-379404A626E4

Q36357215-3C2AC31B-B44E-415E-A1E8-BE235A2548D5

Q36357215-576D3F37-D4B6-4C1E-9B89-28019CC2328F

Q36357215-5F25BB57-F893-4569-8E30-5C014E5604F1

Q36357215-5F7CD807-3CDA-40F8-88C2-2EDB970806D4

P2888

Q36357215-20A29E3F-51CF-4847-8C83-7E45C15566BD

P304

Q36357215-5ADB73D4-DC39-466C-AF61-DE7C0067511A

P31

Q36357215-88E4AD69-5141-4188-AE56-B9DA14262827

P356

Q36357215-399B0EB5-51B0-46DB-86E6-D177DB0C124E

P433

Q36357215-11E77DA0-B41F-41BF-B749-06A46D8B9A92

P478

Q36357215-B7D650FA-0F2E-45F6-8DE5-0C88620D665F

P577

Q36357215-50B08B60-C4DD-4C3D-BD6D-1401A55FF03D

P5875

Q36357215-39F9144D-EC85-4116-8A3C-C18E4C7D0F31

P698

Q36357215-0A51CD62-884C-4A7D-BC46-60AD6B5BF96D

P932

Q36357215-8286AB84-50EE-4D35-806E-BA63935D1420

P356

S10637-011-9790-6

P1433

Investigational New Drugs

P1476

Synergistic activity of the Hs ...... small cell lung cancer models.

@en

P2093

Chaohua Zhang

http://www.w3.org/2001/XMLSchema#string

Dan Zhou

http://www.w3.org/2001/XMLSchema#string

David A Proia

http://www.w3.org/2001/XMLSchema#string

Donald L Smith

http://www.w3.org/2001/XMLSchema#string

Jim Sang

http://www.w3.org/2001/XMLSchema#string

Keizo Koya

http://www.w3.org/2001/XMLSchema#string

Kevin P Foley

http://www.w3.org/2001/XMLSchema#string

Manuel Sequeira

http://www.w3.org/2001/XMLSchema#string

Ronald K Blackman

http://www.w3.org/2001/XMLSchema#string

Shuxia Ye

http://www.w3.org/2001/XMLSchema#string

P2860

Targeting the dynamic HSP90 complex in cancer

Multifaceted intervention by the Hsp90 inhibitor ganetespib (STA-9090) in cancer cells with activated JAK/STAT signaling

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

HSP90 and the chaperoning of cancer

Hsp90 is a core centrosomal component and is required at different stages of the centrosome cycle in Drosophila and vertebrates

Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish Lung Cancer Group phase III randomized trial.

Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel.

Global patterns of cancer incidence and mortality rates and trends.

EGFR-mutated lung cancer: a paradigm of molecular oncology.

P2888

s10637-011-9790-6

P304

2201-2209

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10637-011-9790-6

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

30

http://www.w3.org/2001/XMLSchema#string

P577

2012-01-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221731720

http://www.w3.org/2001/XMLSchema#string

P698

22227828

http://www.w3.org/2001/XMLSchema#string

P932

3484281

http://www.w3.org/2001/XMLSchema#string